Gary Dubin

Director at Hillevax

Dr. Gary Dubin is President of Takeda’s Global Vaccine Business Unit (VBU). Based in Zurich, Switzerland, Gary joined Takeda in September 2015 as Head of the VBU’s Global Medical Office where he led the Clinical Development, Regulatory Affairs, Medical Affairs and Pharmacovigilance functions.

Gary has more than 31 years of experience in vaccine research and development. Prior to joining Takeda, he spent 20 years at GlaxoSmithKline Vaccines where he held the role of Vice President and Head, Global Late Clinical Development. During his career at GSK, Gary led global teams responsible for the clinical development and licensure of a broad range of vaccines addressing important unmet medical needs.

Gary received his medical degree from the University of Pennsylvania and completed his Adult Internal Medicine residency training at the University of Colorado. He also completed a fellowship in Clinical Infectious Diseases and a postdoctoral research fellowship in Molecular Virology at the University of Pennsylvania and served as Adjunct Associate Professor of Medicine at the University of Pennsylvania through 2019. Gary holds numerous patents in the vaccine field and has co-authored more than 90 scientific publications.


Org chart

This person is not in the org chart